Biostar Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported sales of $620,138 against $14,176,234 a year ago. Loss from operations was $6,860,303 against $1,073,184 a year ago. Loss before income taxes was $6,844,223 against $661,499 a year ago. Net loss was $6,902,448 or $3.12 per basic and diluted share against $492,427 or $0.22 per basic and diluted share a year ago. For the six months, the company reported sales of $1,421,765 against $21,084,981 a year ago. Loss from operations was $7,528,822 against $1,963,182 a year ago. Loss before income taxes was $7,522,789 against $1,300,474 a year ago. Net loss was $7,522,789 or $3.40 per basic and diluted share against $652,531 or $0.30 per basic and diluted share a year ago. Net cash provided by operating activities was $353,633 against $439,558 a year ago.